Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study.

ABSTRACT:

Objectives

To evaluate the effectiveness of the mRNA-1273 vaccine against SARS-CoV-2 variants and assess its effectiveness against the delta variant by time since vaccination.

Design

Test negative case-control study.

Setting

Kaiser Permanente Southern California (KPSC), an integrated healthcare system.

Participants

Adult KPSC members with a SARS-CoV-2 positive test sent for whole genome sequencing or a negative test from 1 March 2021 to 27 July 2021.

Interventions

Two dose or one dose vaccination with mRNA-1273 (Moderna covid-19 vaccine) ≥14 days before specimen collection versus no covid-19 vaccination.

Main outcome measures

Outcomes included infection with SARS-CoV-2 and hospital admission with covid-19. In pre-specified analyses for each varian

SUBMITTER: Bruxvoort KJ 

PROVIDER: S-EPMC8671836 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature